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Background: As the number of systematic reviews is growing rapidly, we systematically investigate whether
meta-analyses published in leading medical journals present an outline of available evidence by referring to
previous meta-analyses and systematic reviews.
Methods: We searched PubMed for recent meta-analyses of pharmacological treatments published in high impact
factor journals. Previous systematic reviews and meta-analyses were identified with electronic searches of keywords
and by searching reference sections. We analyzed the number of meta-analyses and systematic reviews that were
cited, described and discussed in each recent meta-analysis. Moreover, we investigated publication characteristics
that potentially influence the referencing practices.
Results: We identified 52 recent meta-analyses and 242 previous meta-analyses on the same topics. Of these, 66% of
identified previous meta-analyses were cited, 36% described, and only 20% discussed by recent meta-analyses. The
probability of citing a previous meta-analysis was positively associated with its publication in a journal with a higher
impact factor (odds ratio, 1.49; 95% confidence interval, 1.06 to 2.10) and more recent publication year (odds ratio,
1.19; 95% confidence interval 1.03 to 1.37). Additionally, the probability of a previous study being described by
the recent meta-analysis was inversely associated with the concordance of results (odds ratio, 0.38; 95% confidence
interval, 0.17 to 0.88), and the probability of being discussed was increased for previous studies that employed
meta-analytic methods (odds ratio, 32.36; 95% confidence interval, 2.00 to 522.85).
Conclusions: Meta-analyses on pharmacological treatments do not consistently refer to and discuss findings of
previous meta-analyses on the same topic. Such neglect can lead to research waste and be confusing for readers.
Journals should make the discussion of related meta-analyses mandatory.
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Systematic reviews and meta-analyses represent a high
level of evidence and are invaluable to health profes-
sionals in synthesizing the results of medical research
[1]. The number of systematic reviews is growing rapidly -
in 2010 approximately 11 such studies were published per
day, which corresponds to the number of randomized
controlled trials (RCTs) published three decades ago [2].* Correspondence: bartosz.helfer@gmail.com
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unless otherwise stated.Because of this exponential growth in publication rates,
many meta-analysis authors may not discuss the results of
previous meta-analyses and systematic reviews on the
same topic - in a manner analogous to authors of RCTs
not referring to a substantial portion of other relevant
RCTs [3] or systematic reviews [4,5]. This can be very con-
fusing for readers and cause waste in research resources
[6], including waste in study planning [7], design, and con-
duct [8] as well as leading to unnecessary duplications [9]
and incomplete reporting [10,11].
To grasp the importance of such neglect, imagine cli-
nicians seeking a treatment solution for a patient’sThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Helfer et al. BMC Medicine  (2015) 13:82 Page 2 of 8specific medical problem. They find two similar meta-
analyses with discordant results. If the newer article does
not refer to the older, the readers are given no explan-
ation about the possible reasons for this discrepancy.
Which article should they trust more? Their level of un-
certainty is higher than before reading the authoritative
articles and an evidence-based decision regarding their
patients’ treatment even more difficult. Not referring to
important related research is also against the principles
of evidence-based medicine, because meta-analysts agree
that all available evidence should be systematically
searched and reviewed in an unbiased manner [12].
Moreover, as for all types of research, the question a
meta-analysis is trying to answer should be relevant
[7-9]. If the question has been already answered in a pre-
vious meta-analysis, the authors should clearly justify
why they decided to perform a similar analysis again. Is
it a replication, an update, or maybe just an unnecessary
duplication?
To provide patients, clinicians, and policymakers with
the most useful information about a clinical question,
meta-analyses should not neglect previous systematic re-
views about the same topic. This will not only help to
provide a more complete understanding of the clinical
problem, but also to avoid research waste and biased
results.
We report a systematic investigation of whether recent
meta-analyses published in the leading medical journals
cite, describe, and discuss previous meta-analyses and
systematic reviews on the same topic. We also analyze
factors that are likely to be associated with this
phenomenon.
Methods
First, we identified a sample of recent meta-analyses,
then for each included recent article we performed a
separate systematic search to find similar previous meta-
analyses and systematic reviews. Our goal was to esti-
mate what proportion of the previous meta-analyses and
systematic reviews was cited, described, and discussed
by the recent meta-analyses. We also investigated po-
tential predictors of citing, describing, and discussing.
We initially published a protocol at our institutional
website [13].
Selection of the recent meta-analyses
We searched PubMed, combining the names of the six
general medical journals with the highest impact factors
according to Journal Citation Records, 2013 edition
(New England Journal of Medicine, The Lancet, JAMA:
The Journal of the American Medical Association,
Annals of Internal Medicine, PLOS Medicine, British
Medical Journal) and ‘meta-analysis’ as publication type
(see Additional file 1). To produce a more homogenoussample we only included meta-analyses on pharmaco-
logical treatments. The original search was completed in
March 2013. We aimed to include at least 50 published
meta-analyses. We expanded the search to January 2012
to meet this criterion.
We then systematically assessed citation habits of
these recent meta-analyses towards previous meta-
analyses and systematic reviews on the same topic.
Selection of the previous meta-analyses and systematic
reviews
For each recent meta-analysis we searched PubMed for
previous meta-analyses and systematic reviews on the
same topic (unlike recent articles, previous studies also
included systematic reviews without meta-analysis),
combining the keywords provided by the recent articles
with ‘meta-analysis’ or ‘systematic review’ as publication
type (see Additional file 2). The keywords were based on
the characteristics of the participating population and
the intervention(s) used. The reference lists of all in-
cluded studies were also screened. We compared PICO
questions between the recent and the previous articles
in order to make sure that they focus on a similar group
of participants (P) and use similar interventions (I), com-
parators (C), and outcomes (O) [14]. Previous articles
which had any of the PICO questions completely differ-
ent from the corresponding questions in the recent art-
icle were excluded. Additionally, for included previous
articles we calculated a ‘similarity score,’ such as for each
PICO question one or zero points were given, depending
whether all of the four PICO questions were identical to
the corresponding questions from the recent article (one
point per question was given if that was the case) or
whether the questions were only overlapping. That was
the case when the criteria for each PICO question were
only partially similar, for example when multiple out-
comes were used and only some of them were employed
by the previous study (in such a case zero points were
given, but the study was not excluded). For more details
and examples of this similarity score see Additional
file 3. We also excluded articles published more than
10 years or less than 1 year from the time of publica-
tion of the recent meta-analysis, unless they were cited
in the recent meta-analysis. This criterion ensured that
we did not analyse outdated material and it also does
justice to the fact that the publication process can take
a long time.
Statistical analysis of predictors
Our primary question was to estimate what proportion
of the previous meta-analyses and systematic reviews
was cited (that is, whether a reference to the previous
article was provided by the recent study), described (that
is, whether any information about the results of the
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whether the results from the previous article were re-
lated to the results or conclusions from the recent study)
by the recent meta-analysis. Table 1 provides specific ex-
amples for each definition.
We also investigated potential predictors of citing,
describing, and discussing previous meta-analyses and
systematic reviews by recent meta-analyses using mixed-
effects logistic regression analysis in R.
Recent article-specific predictors included: journal
title, medical discipline, journal impact factor (based on
Journal Citation Records, 2013 edition), and quality of
the systematic review as measured with the AMSTAR
score (a measurement tool for the assessment of the
methodological quality of systematic reviews) [21].
Previous article-specific predictors included: level of
similarity of the review question (based on comparison
of PICO questions between recent and previous article),
journal impact factor, publication year, article type
(systematic review using meta-analytic methods versus
not), and concordance of results between recent and
previous articles (similar results versus different results).
Results were judged as ‘similar’ when the direction of
the effect was the same, irrespective of the effect size. In
general, concordance of results was based on the major
findings of the study (primary outcome, if possible) and,
if necessary, particular results and conclusions were
compared, including strength of evidence. In case of pre-
vious systematic reviews without meta-analysis, concord-
ance was based on the main message of the paper, that
is, the authors’ summary and/or conclusions (illustrating
examples are presented in Additional file 4). To avoid
confusion we emphasize that the term ‘similarity’ refers
to a comparison of the recent and previous articles
in terms of the review questions, whereas the termTable 1 Cited versus described versus discussed: definitions a
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Discussed Results from the previous article were related to the








these‘concordance’ refers to a comparison of recent and pre-
vious article results.
In a sensitivity analysis we excluded previous articles
published before 2010 to check whether the general pat-
tern of results changed in the newer papers.
BH piloted the analysis on a sample of 10 studies,
selecting and extracting all the data. AP independently
extracted a random sample of 25%. An inter-rater reli-
ability analysis using the Kappa coefficient was per-
formed to determine the consistency among raters [22].
Conflicts were resolved by discussion between BH and
AP; if necessary, SL was involved. Results of the regres-
sion analyses are presented as odds ratios (OR) and as-
sociated 95% confidence intervals (CI).
Results
We identified 52 recent meta-analyses and 242 previous
meta-analyses and systematic reviews (including 24 pre-
vious systematic reviews without meta-analysis), cover-
ing a wide range of drugs and medical specialties.
Table 2 shows summary characteristics of included
studies, whereas Additional files 5 and 6 provide de-
tailed information on the individual meta-analyses and
systematic reviews.
Out of 52 recent meta-analyses there were only four
without previously published meta-analyses or system-
atic reviews. These four articles were excluded from the
regression analysis. For the remaining 48 articles there
were, on average, five (range 1 to 28, SD 4.6) previous
meta-analyses or systematic reviews per paper.
Out of 242 previous meta-analyses and systematic re-
views, approximately two-thirds were cited (159 out of
242, 66%), one-third described (86 out of 242, 36%), and
only one-fifth discussed in the recent meta-analyses (49
out of 242, 20%). This pattern of results did not changend examples
ple
nt meta-analysis on probiotics [15] cited a previous meta-analysis [16]
tting the reference (number 91) at the end of this sentence: ‘The
tive of this study was to evaluate broadly the available evidence on
tic interventions for the prevention and treatment of AAD, building
evious nonsystematic overviews and systematic reviews on selected
ations [1,2,8,11,89-91].’
nt meta-analysis on dual blockade of the renin-angiotensin system [17]
bed the results from a previous meta-analysis [18] by saying, ‘One
analysis reported ‘encouraging’ evidence that dual therapy reduced
inuria by an incremental 20-25% compared with monotherapy.’
nt meta-analysis on oral anticoagulants [19] discussed the results from
ious systematic review [20] by saying, ‘Loke and Kwok published an
ed indirect comparison of rivaroxaban and dabigatran based on studies
ute venous thromboembolism prophylaxis in orthopaedics, with low
ular weight heparin as the common comparator. Rivaroxaban was found
superior to dabigatran, but there was a trend towards increased bleeding.
ences in therapeutic regimen and selection of patients could explain
discrepancies with our results.’
Table 2 Summary characteristic of included studies
Journal Recent Previous
Annals of Internal Medicine 9 17% 54 22%
British Medical Journal 24 46% 117 48%
JAMA 7 13% 32 13%
New England Journal of Medicine 1 2% 9 4%
PLOS Medicine 5 10% 12 5%
The Lancet 6 12% 18 7%
Total: 52 242
Mean AMSTAR score for recent meta-analyses 8.5 (SD 1.5)
Mean impact factor for previous studies 7.7 (SD 8.8)
Previous SRs with meta-analysis 218
Previous SRs without meta-analysis 24
Number of previous studies for a recent meta-analysis 0 to 28 (mean 4.65; SD 4.65)
Mean length of time from publication year previous to recent study 3.6 years (SD 2.5)
Mean similarity score between previous and recent studies 1.8 points (SD 1.1, range 0 to 4)
‘Recent’ refers to the initially identified meta-analyses and ‘previous’ refers to the previous meta-analyses or systematic reviews (SRs) on the same topic. More
detailed information on all the individual studies is presented in Additional files 5 and 6. SD, standard deviation.
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is, older than two years) were excluded (see Figure 1).
Citing a previous meta-analysis or systematic review
by a recent meta-analysis was positively associated with
publication of the previous article in a journal with a
higher impact factor (OR, 1.49; 95% CI, 1.06 to 2.10)
and more recent publication year (OR, 1.19; 95% CI,
1.03 to 1.37). Similar results were found for describing
(higher impact factor: OR, 1.83; 95% CI, 1.27 to 2.62;
more recent publication year: OR, 1.29; 95% CI, 1.08
to 1.55) as well as for discussing (higher impact factor:
OR, 1.72; 95% CI, 1.16 to 2.55; more recent publication













Previous studies published after 20
Figure 1 Results of the primary analysis. Percentage of previous meta-anal
by the recent meta-analyses.probability of describing the previous article was in-
versely associated with the concordance of results (OR,
0.38; 95% CI, 0.17 to 0.88) and the probability of being
discussed was increased for previous articles that
employed meta-analytic methods (OR, 32.36; 95% CI,
2.00 to 522.85). The AMSTAR score of the recent meta-
analysis as well as the similarity score were not signifi-
cantly associated with any of the outcomes (see Table 3)
and the nominal variables journal title and medical dis-
cipline were excluded from the regression analysis.
The inter-rater reliability for the independent raters








12 (n=99) All previous studies (n=242)
yses and systematic reviews that were cited, described, and discussed
Table 3 Results of the regression analysis
Study characteristic OR (95% CI) P-value
Cited
Impact factor 1.49 (1.06 to 2.10) 0.021
Publication year 1.19 (1.03 to 1.37) 0.018
Concordance of results 0.92 (0.46 to 1.86) 0.814
Meta-analytic method used 1.41 (0.45 to 4.46) 0.549
Similarity of the review question 0.99 (0.94 to 1.05) 0.789
AMSTAR score 1.10 (0.79 to 1.53) 0.569
Described
Impact factor 1.83 (1.27 to 2.62) 0.001
Publication year 1.29 (1.08 to 1.55) 0.006
Concordance of results 0.38 (0.17 to 0.88) 0.023
Meta-analytic method used 3.42 (0.82 to 14.34) 0.092
Similarity of the review question 1.01 (0.94 to 1.08) 0.757
AMSTAR score 1.00 (0.99 to 1.00) 0.136
Discussed
Impact factor 1.72 (1.16 to 2.55) 0.007
Publication year 1.55 (1.17 to 2.06) 0.002
Concordance of results 0.40 (0.14 to 1.12) 0.081
Meta-analytic method used 32.36 (2.00 to 522.85) 0.014
Similarity of the review question 0.92 (0.83 to 1.02) 0.116
AMSTAR score 0.76 (0.43 to 1.34) 0.345
Associations between characteristics of the previous studies and odds to be
cited, described, and discussed by the recent meta-analyses (as well as the
AMSTAR score of the recent articles). Statistically significant results (P ≤ 0.05)
are highlighted in bold. CI, confidence interval; OR, odds ratio.
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We found that in recent meta-analyses on pharmaco-
logical interventions published in leading medical jour-
nals, the proportion citing, describing, or discussing
previous meta-analyses and systematic reviews on the
same topic was low. Specifically, we found that only
two-thirds of previous meta-analyses and systematic re-
views were cited, one-third described, and only one in
five of the previous articles’ results was discussed in light
of the recent meta-analysis’ findings.
For individual RCTs it has been pointed out that most
new trials are not interpreted, planned, and designed in
the context of existing systematic reviews and other rele-
vant evidence [6,23]. Our findings suggest that this state-
ment applies also to otherwise methodologically sound
meta-analyses. A fundamental principle of meta-analyses
and systematic reviews is that all relevant clinical trials
should be considered. We believe that they should also
outline previous meta-analyses and systematic reviews
about the same topic. Understanding the existing lit-
erature is central to any new project. In case of a
meta-analysis, not referring to the results of previous
meta-analyses and systematic reviews is especiallyproblematic because it is likely to lead to confusion
and disinformation among clinicians, patients, and policy-
makers, which is exactly the opposite of what any effort
aiming at synthesizing scientific findings should be.
One could argue that citing 65% of previous relevant
meta-analyses and systematic reviews is not a bad result,
but we believe that simply putting a reference to another
review is not enough. Systematic reviewers should place
their results in the context of previous reviews, that is,
provide a meaningful comment, comparison, or explan-
ation of existing differences.
Moreover, this neglect is an example of inadequate
study planning, suggesting that many authors do not
perform the necessary literature search before initiating
their own project [7,24]. This might very well be one of
the reasons behind unnecessary duplication of effort in
health sciences [8]. As trenchantly expressed by Terry
and colleagues, ‘The issue of knowing what research is
currently being undertaken … is a black hole in the pub-
lic health landscape’ [25]. Especially worrisome is the
fact that the authors who refer to similar previous papers
rarely justify why their own project was undertaken,
given a similar work was recently performed. In our
sample we found 10 recent meta-analyses referring to a
very similar previous work (‘similarity score’ four out of
four). Only six of them justified why the same analysis
was performed again (most common reason being that
the previous paper needs to be updated or that some
discordant results require clarification). None of them
mentioned rigorous replication as a reason, suggesting
that an ‘efficient culture for replication of research’ [8]
has yet to emerge in health sciences.
Predictors
We found that this neglect to refer to previously pub-
lished systematic reviews and meta-analyses was pre-
dicted by a number of variables. According to our
model, previous meta-analyses and systematic reviews
were more likely to be cited, described, or discussed by a
recent meta-analyses if recently published in a journal
with a high impact factor, if results were different, and if
meta-analytic methods were used.
Publication year
More-recent meta-analyses are simply more up to date
and usually include more RCTs. However, this does not
necessarily mean that an older meta-analysis should be
neglected - depending, among other factors, on how
many new studies have been published since, an older
meta-analysis can still serve as a valuable source of in-
formation that should be included in the literature re-
view. Importantly, when we excluded all the previous
articles published before 2010, the general pattern of our
main result did not change (see Figure 1), showing that
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systematic reviews and meta-analyses persisted even for
the most recent material.
Impact factor
Our results show that for an increase of one unit in
impact factor the odds to get cited by a recent meta-
analysis increased by 49%. Although criticized, impact
factor is an important criterion for readers to assess
the importance of scientific literature [26]. However,
authors of systematic reviews should be especially
careful not to miss important insights published out-
side high-impact-factor journals and select evidence
on grounds of methodological validity rather than sim-
ply high visibility [27].
Different results
We hypothesize that omitting similar findings from pre-
vious papers may constitute an (un)conscious strategy
performed by authors to artificially create ‘novelty value’
to win an advantage during the peer-review and publica-
tion process. This is because journals demand novel,
ground-breaking results to qualify for acceptance [28] -
revealing that another article, using similar methodology,
has obtained the same results likely decreases the nov-
elty of the submitted paper. Such acts distort readers’
understanding of the true landscape of the medical
evidence.
Meta-analytic methods
Although it is generally acknowledged that meta-analysis
can be an important and reliable source of information
[29], we would like to emphasize that the methodology
itself cannot be a synonym of scientific quality and
authors should be aware of both strengths and weak-
nesses of this method [30].
Limitations
Our analysis has limitations. We decided to focus only
on clinical journals with the highest impact factors, be-
cause they usually publish papers of high scientific qual-
ity [31]. Nevertheless, our sample may not be considered
representative for all medical meta-analyses. Because we
wanted to be systematic in our approach, we included
New England Journal of Medicine, although it does not
publish many systematic reviews. We also restricted our-
selves to pharmacological interventions. Therefore, our
results do not necessarily generalize to other forms of
treatment or other journals although we do not see any
obvious reasons why the situation there should differ.
We only used PubMed to identify the previous articles,
so we might have missed some relevant meta-analyses or
systematic reviews about a given topic. However, be-
cause we always included all previous meta-analyses andsystematic reviews cited by the recent article (that is, all
previous systematic reviews and meta-analyses that were
on the reference list of a given recent article), our results
represent a rather conservative estimate of the propor-
tion of the previous meta-analyses and systematic re-
views that were cited, described, and discussed by the
recent meta-analyses. Selection by a single reviewer and
25% double extraction was also a limitation of our study,
but the level of agreement between reviewers was good
according to the Kappa coefficient [22]. Moreover, this is
not a review where exact accuracy is essential - our pri-
mary result is very robust and our conclusions would
not change even if the number of discussed and de-
scribed papers should increase by a factor of two. Finally,
our detailed description of the results in the Additional
files allows verification and replication (see Additional
file 7 for a list of references to all included meta-
analyses and systematic reviews).
As we are not aware of any other research that could
have guided our selection of predictors, we chose them
based on our own expertise. Because of that, some of
the measures we used have not been previously validated
(similarity score of the review question, concordance of
results), but we made sure they were as simple as pos-
sible and well-operationalized (including a priori defini-
tions wherever possible). Moreover, the similarity score
was based on the PICO questions that are considered es-
sential in defining which studies to include and exclude
[14] and constitute a well-recognized procedure [32].
Conclusions and policy implications
Upcoming systematic reviews and meta-analyses should
include an outline of previous systematic work about the
same topic. Such an outline should be recommended by
evidence-based medicine guidelines and officially imple-
mented by the editorial policies. Currently, the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement recommends that authors
of systematic reviews explain in the introduction how
their work adds to what is already known and explain
whether is it a new review or an update (see item 3:
Rationale) [33]. This is not sufficient. In this respect the
Consolidated Standards of Reporting Trials (CONSORT)
Statement seems more demanding, recommending that
each new trial includes a reference to a systematic re-
view of previous similar trials or a note of the absence
of such trials (see item 2a: Scientific background and
explanation of rationale) [34]. We feel that there is no
reason why systematic reviews should not follow an
analogous procedure. The Cochrane Collaboration
already acknowledged this problem and includes an
obligatory section ‘Agreements and disagreements
with other studies or reviews’ in its software Review
Manager [35].
Helfer et al. BMC Medicine  (2015) 13:82 Page 7 of 8To reduce unnecessary duplication of research effort
and adequately determine whether there is a need to
undertake a new project, all systematic reviews and meta-
analyses should be prospectively registered [8] using inter-
national registries of protocols, like PROSPERO [36].
Limiting the failure to refer to what is already known
would make systematic reviews and meta-analyses a
more useful, transparent, and valuable source of infor-
mation for clinicians, researchers, policymakers, and
patients. This simple step towards clarity and inform-
ativeness would enhance evidence-based practice as well
as reduce waste in research resources [6-8,10,37] and re-
duce human suffering [38].
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